NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 195 filers reported holding NEKTAR THERAPEUTICS in Q3 2016. The put-call ratio across all filers is 0.95 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2017 | $1,399,000 | -90.2% | 58,300 | -94.2% | 0.00% | -90.0% |
| Q2 2016 | $14,270,000 | +22.9% | 1,002,832 | +18.8% | 0.03% | +25.0% |
| Q1 2016 | $11,607,000 | -4.2% | 844,113 | +17.4% | 0.02% | 0.0% |
| Q4 2015 | $12,116,000 | +74.4% | 719,060 | +13.4% | 0.02% | +71.4% |
| Q3 2015 | $6,949,000 | -9.4% | 633,999 | +3.3% | 0.01% | 0.0% |
| Q2 2015 | $7,674,000 | +14.8% | 613,458 | +0.9% | 0.01% | +16.7% |
| Q1 2015 | $6,687,000 | – | 607,868 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 2,000,000 | $67,200,000 | 3.35% |
| First Light Asset Management, LLC | 763,403 | $25,650,000 | 3.33% |
| BRIDGER MANAGEMENT, LLC | 1,238,489 | $41,613,000 | 3.29% |
| Rhenman & Partners Asset Management AB | 734,445 | $24,677,000 | 2.89% |
| BB BIOTECH AG | 2,020,676 | $67,895,000 | 1.71% |
| Gs Investments, Inc. | 54,200 | $1,821,120,000 | 1.43% |
| Artal Group S.A. | 900,000 | $30,240,000 | 1.24% |
| Cormorant Asset Management, LP | 500,000 | $16,800,000 | 1.14% |
| TOBAM | 640,547 | $21,522,000 | 1.09% |
| Bellevue Group AG | 430,026 | $14,449,000 | 0.80% |